Overview

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
To determine the impact of maintenance therapy in patients with MDS/AML in remission.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
Azacitidine
Cytarabine
Sargramostim